Drugs / Vic-trastuzumab duocarmazine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04602117 | Jul → Nov 2021 | HER2 positive breast carcinoma, carcinoid tumor, endometrium neoplasm, gastroesophageal adenocarcinoma +6 | QuantumLeap Healthcare Collaborative | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vic-trastuzumab duocarmazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04602117 ↗ |
| Route | Intravenous | “Eligible patients will receive infusions of SYD985 every three weeks” NCT04602117 ↗ |